Circulating MicroRNAs as Potential Diagnostic Biomarkers for Heart Failure: A Systematic Review and Meta-Analysis

This systematic review and meta-analysis of 86 studies identifies a panel of 71 consistently dysregulated circulating microRNAs, with miR-21 and miR-423-5p emerging as high-quality, robust diagnostic biomarkers for heart failure, while highlighting the need for standardized protocols to address heterogeneity across species and sample types.

The Gist

Imagine your heart is a busy city. When the city starts to struggle (Heart Failure), it sends out distress signals. For decades, doctors have relied on a few old, well-known "emergency flares" (like BNP) to know the city is in trouble. But these flares have problems: sometimes they go off when the city is just having a party (false alarms), and sometimes they don't go off at all when the city is actually burning down (missed diagnoses), especially in a specific type of heart failure called HFpEF.

This paper is like a massive detective agency report that went out to find better, more reliable distress signals. They looked for tiny, invisible messengers called microRNAs (miRNAs). Think of miRNAs as the city's "text messages" or "whispers" that float in the bloodstream, telling the truth about what's happening inside the heart.

Here is the story of what they found, broken down simply:

1. The Great Detective Hunt (The Method)

The researchers didn't just guess; they went on a digital treasure hunt. They gathered 86 different studies (like collecting 86 different police reports) from all over the world, involving over 3,000 people and animals. They wanted to see which "text messages" (miRNAs) were consistently different in people with heart failure compared to healthy people.

2. The Suspects: Who is Talking Too Much? Who is Too Quiet?

Out of hundreds of potential suspects, they found 71 miRNAs that were acting strangely in heart failure patients.

• The Loud Shouters (Upregulated): These were the messages screaming too loudly. The biggest shouters were miR-21 and miR-423-5p. Imagine miR-21 as a siren that is blaring at maximum volume in almost every heart failure city. It was so consistent that the researchers felt very confident about it.
• The Muted Whispers (Downregulated): These were the messages that went silent. miR-144 and miR-126 were the ones that went quiet when they should have been speaking up.

3. The "Trust Score" (The GRADE System)

Just because a signal is loud doesn't mean it's reliable. Maybe it's just a glitch in one specific city. To solve this, the team used a special "Trust Score" system (called GRADE). They rated the evidence like a movie rating system:

• ⭐⭐⭐⭐⭐ (High Quality): These are the "Blockbuster Hits." miR-21, miR-423-5p, miR-221, miR-1, and miR-148a got 5 stars. They were found in many studies, in many different countries, and in different types of blood samples. These are the ones doctors should trust most.
• ⭐⭐⭐ (Moderate Quality): Good movies, but maybe a bit shaky. miR-144 and miR-27a got 3 stars. They look promising, but we need more proof.
• ⭐ (Low/Very Low Quality): These are the "Indie films" with small budgets. Many other miRNAs were found, but only in a few studies or mostly in rats (animal models). We aren't sure if they work the same way in humans yet.

4. The Plot Twists (Subgroup Analysis)

The detectives noticed some interesting differences:

• Species Differences: In human studies, some signals went quiet (downregulated), but in rat studies, almost everything was screaming (upregulated). It's like how a dog might bark at a mailman, but a human just ignores them. You can't always translate animal results directly to humans.
• Cultural Differences: Some signals were loud in Asian populations but quiet in non-Asian populations. This suggests that in the future, we might need different "diagnostic kits" for different parts of the world.
• Sample Types: It mattered where the blood was taken from. Some signals were loud in serum (the liquid part of blood after it clots) but quiet in plasma (liquid before it clots). miR-21 was the only one that was loud in both, making it a very stable candidate.

5. The Verdict (Conclusion)

The main takeaway is this: We have found a new, better set of tools.

While the old tools (BNP) are still useful, they aren't perfect. This study says, "Hey, if you want to diagnose heart failure early and accurately, start by checking miR-21 and miR-423-5p." They are the most reliable "text messages" the heart sends out.

However, the researchers warn that before these new tools can be used in every hospital, we need to standardize how we test for them (making sure everyone measures the "volume" the same way) and run bigger tests to confirm they work for everyone, regardless of their ethnicity or the specific type of heart failure they have.

In short: This paper is a roadmap. It tells us which tiny biological messengers are the most trustworthy guides for navigating the complex city of Heart Failure, helping us move from "guessing" to "knowing."

Technical Summary

1. Problem Statement

Heart failure (HF) remains a leading cause of global morbidity and mortality. While established biomarkers like B-type Natriuretic Peptide (BNP) and NT-proBNP are standard, they suffer from significant limitations:

• Low Specificity: Levels are confounded by age, renal impairment, obesity, and atrial arrhythmias.
• Diagnostic Gaps: Their accuracy is particularly uncertain in Heart Failure with Preserved Ejection Fraction (HFpEF).
• Need for Novel Markers: There is an urgent need for biomarkers with higher specificity and robustness for early detection and risk stratification.

Circulating microRNAs (miRNAs) have emerged as promising candidates due to their stability in peripheral blood, tissue-specific expression, and role in regulating pathological processes like myocardial hypertrophy and fibrosis. However, previous systematic reviews were limited by small sample sizes and a lack of comprehensive subgroup analyses regarding ethnicity and sample types.

2. Methodology

The study employed a rigorous systematic review and meta-analysis framework adhering to PRISMA guidelines.

• Data Sources & Search Strategy: A comprehensive search was conducted across PubMed, Embase, and Cochrane Central from inception to March 2025. The search focused on English-language studies comparing miRNA expression in HF patients versus healthy/non-HF controls.
• Inclusion Criteria:
  • Original studies (human or animal) comparing HF and control groups.
  • Samples derived from blood (plasma, serum, whole blood) or myocardial tissue.
  • Use of established detection methods (qRT-PCR, microarray, sequencing).
  • Availability of extractable expression data and sample sizes.
• Study Selection: From an initial pool of 3,702 articles, 86 studies were included (61 human studies with 2,812 samples; 25 animal studies with 211 samples).
• Quality Assessment:
  • Human Studies: Assessed using the Newcastle-Ottawa Scale (NOS).
  • Animal Studies: Assessed using the SYRCLE's risk of bias tool.
• Statistical Analysis:
  • Model: Random-effects model was used to pool effect sizes.
  • Metric: Logarithmic odds ratios (logOR) with 95% Confidence Intervals (CI) were calculated to determine upregulation (positive logOR) or downregulation (negative logOR).
  • Subgroup Analyses: Conducted based on species (human/animal), ethnicity (Asian/non-Asian), and sample type (serum/plasma/tissue).
• Evidence Grading: The GRADE (Grading of Recommendations Assessment, Development, and Evaluation) framework was applied to classify the quality of evidence for each miRNA (High, Moderate, Low, Very Low). This involved evaluating risk of bias, inconsistency, indirectness, imprecision, and publication bias, with potential upgrades for large effect sizes or cross-validation.

3. Key Contributions

• Expanded Dataset: This is the most comprehensive meta-analysis to date, incorporating 31+ new high-quality studies not present in previous reviews, totaling 3,023 samples.
• Multi-Dimensional Stratification: Unlike prior reviews, this study systematically analyzed heterogeneity across ethnicity (Asian vs. non-Asian) and sample source (serum vs. plasma vs. tissue), providing a nuanced view of biomarker stability.
• Evidence-Based Prioritization: The application of the GRADE framework moves beyond simple statistical significance to provide a clinical priority list, distinguishing between robust, high-confidence biomarkers and exploratory candidates.
• Identification of Novel Candidates: It identifies and validates a broader panel of dysregulated miRNAs than previously established.

4. Key Results

Overall Findings:

• 71 Consistently Dysregulated miRNAs were identified across the 86 studies.
  • 58 Upregulated: Including miR-21, miR-423-5p, miR-210, miR-221, and miR-148a.
  • 13 Downregulated: Including miR-144, miR-126, and miR-129.
• Top Performer: miR-21 showed the most significant upregulation (logOR = 8.15, 95% CI: 7.55–8.74) and was validated in 15 independent studies (n=722).

Subgroup Analysis Insights:

• Species Differences: Human studies frequently showed downregulated miRNAs, whereas animal models predominantly showed upregulation, highlighting the difficulty in translating preclinical data.
• Ethnicity:
  • Cross-Ethnic Stability: miR-21, miR-148a, miR-221, miR-423-5p, and miR-622 were consistently upregulated in both Asian and non-Asian populations.
  • Ethnic Specificity: Some miRNAs (e.g., let-7i-5p, miR-129) showed dysregulation only in specific ethnic groups.
• Sample Type:
  • Blood vs. Tissue: Correlations between tissue and blood data were modest.
  • Serum vs. Plasma: miR-21 demonstrated consistent upregulation in both serum and plasma, making it a highly stable candidate. miR-423-5p was the most significant in plasma, while miR-129-5p was the sole downregulated marker in serum.

GRADE Evidence Grading:

• High-Quality Evidence (Top Priority): miR-1, miR-21, miR-221, miR-423-5p, and miR-148a. These met criteria for large effect sizes, cross-group consistency, and multi-study validation.
• Moderate-Quality Evidence: miR-144 and miR-27a.
• Low/Very Low-Quality Evidence: Included miR-210 (downgraded due to small sample size and indirectness from animal data) and the majority of animal-only studies.

Sensitivity Analysis:
Excluding small-sample studies (n ≤ 10) confirmed that the overall expression profile remained stable, with only minor variations, reinforcing the robustness of the primary findings.

5. Significance and Conclusion

• Clinical Translation Roadmap: The study provides a clear, evidence-graded hierarchy for clinical validation. miR-21 and miR-423-5p are identified as the most robust candidates for immediate translation into diagnostic assays.
• Precision Diagnostics: The findings underscore that a "one-size-fits-all" approach is insufficient. Future diagnostic panels must account for ethnicity and sample type (serum vs. plasma) to ensure accuracy.
• Standardization Needs: The heterogeneity observed highlights the critical need for standardized protocols in miRNA extraction, detection, and normalization to facilitate multi-center validation.
• Future Directions: The authors recommend large-scale, prospective, multicenter trials focusing on the high-priority miRNAs identified, as well as integrating miRNA panels with existing markers (BNP/NT-proBNP) to improve diagnostic specificity, particularly for HFpEF.

In summary, this meta-analysis establishes a refined, high-confidence panel of circulating miRNAs for heart failure diagnosis, offering a strategic framework for moving these biomarkers from research to clinical practice.